Investor Presentation
107
Investor presentation First six months of 2022
International Operations at a glance.
Novo NordiskⓇ
Diabetes trend
Million
600
400
200
0
11
487
2021
587
2030
Population with diabetes
Diabetes growth rate
DKK
19%
billion
250
17%
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
First half of 2022
Sales
(mDKK)
Growth²
80%
Total GLP-13
12,013
53%
Long-acting insulin4
6,020
4%
200
34.0%¹
60%
Premix insulin5
5,242
-8%
Fast-acting insulin
5,689
0%
150
Insulin
Human insulin
3,375
-18%
720
4.7%¹
40%
Total insulin
20,326
-5%
100
Other Diabetes care?
1,331
-11%
20%
Diabetes care
33,670
10%
50
7.4%1
OAD
Obesity care
2,480
60%
0
May
2045
2017
0%
Diabetes & Obesity
36,150
12%
May
2022
care
Rare disease⁹
6,453
1%
GLP-1 MS -Insulin MS
-OAD MS
Total
42,603
10%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of May 2022: Novo Nordisk 50%, Sanofi 27% and Eli Lilly 14%;
Competitor GLP-1 value market shares, as of May 2022: Novo Nordisk
60%, Eli Lilly 37% and AstraZeneca 2%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, May 2022 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 5 Comprises RyzodegⓇ and
NovoMixⓇ: 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®: 9 Comprises
primarily NovoSeven®, Novo Eight® NovoThirteen®, Refixia®, Esperoct®,
Norditropin, Vagifem® and Activelle®
Source: Quarterly company announcementView entire presentation